Add time:07/16/2019         Source:sciencedirect.com

Acetoxycycloheximide (cas 2885-39-4) (ACH), the most potent inhibitor of protein synthesis in mammalian tissues, was administered to female rats in order to investigate the relationship of hepatic protein synthesis inhibition to the pathogenesis of fatty liver. Groups of animals were sacrificed at intervals between 1.5 and 24 hr after receiving ACH, by ip injection, in concentrations of either 0.25 or 0.50 mgm/kgm body weight. Blood samples were analyzed for triglyceride and free fatty acid (FFA) content, and hepatic triglycerides were determined. ACH produced neither an increase in hepatic triglyceride content, a depression of plasma triglycerides nor an elevation of FFA. Electron microscopy of the liver failed to demonstrate lipid accumulation. The plasma lipoproteins of ACH-treated rats had normal triglyceride and protein contents. These resutls demonstrate that hepatic protein synthesis inhibition alone is not sufficient to produce liver triglyceride accumulation and emphasize the importance of FFA mobilization in the pathogenesis of fatty liver.

We also recommend Trading Suppliers and Manufacturers of Acetoxycycloheximide (cas 2885-39-4). Pls Click Website Link as below: cas 2885-39-4 suppliers